- $1.28bn
- $1.72bn
- $348.97m
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children
Brief: Mannkind Says Afrezza Available To Eligible Patients For $35 Or Less Per Month
Brief: Mannkind Says FDA Releases Company From Postmarketing Requirement For Afrezza On May 27 - SEC Filing
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
MannKind falls after quarterly revenue miss
MannKind Q1 revenue rises 15% but swings to net loss
U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
U.S. STOCKS ON THE MOVE-DaVita, Knight-Swift, Madrigal Pharma
U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber
U.S. STOCKS ON THE MOVE-AMD, Apollo, Deckers Outdoor
MannKind rises as it partners with United Therapeutics on inhaled drug for rare lung disease
MannKind Q4 revenue rises 46% as Furoscix sales surge
Brief: Mannkind Announces First Patient Enrolled In Inhale-1St Pediatric Study Evaluating Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (T1d)
U.S. STOCKS ON THE MOVE-Apple, Belite Bio, Bank of Marin Bancorp
U.S. STOCKS ON THE MOVE-US natgas companies